AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8743403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 500 mg
Number of subjects: 36
Study 8743403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 1000 mg
Number of subjects: 36
Study 8743403 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin 250 mg
Number of subjects: 36
Study 8743403 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin 500 mg
Number of subjects: 36
Study 8743403 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin 1000 mg
Number of subjects: 36
Study 8743403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil
Number of subjects: 36
Study 8743403 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin
Number of subjects: 36
Study 8743403 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cefadroxil and cephalexin
Number of subjects: 36
Study 1672589 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychoeducation
Number of subjects: 0
Study 1672589 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training
Number of subjects: 0
Study 1672589 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of family psychoeducation and social skills training
Number of subjects: 0
Study 1672589 — intervention group
Group type: COMPARATOR
Intervention: Social skills training alone
Number of subjects: 0
Study 1672589 — intervention group
Group type: COMPARATOR
Intervention: Family condition or combined family/social skills condition
Number of subjects: 0
Study 7293945 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg/day)
Number of subjects: 30
Study 7293945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31072599 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (ImRs)
Number of subjects: 0
Study 31072599 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing Rescripting (WRs)
Number of subjects: 0
Study 31072599 — intervention group
Group type: COMPARATOR
Intervention: Recall only (ImRE)
Number of subjects: 0
Study 31072599 — intervention group
Group type: COMPARATOR
Intervention: No recall + no manipulation (NM)
Number of subjects: 0
Study 31030986 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) programme
Number of subjects: 8482
Study 31030986 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 8482
Study 28874242 — intervention group
Group type: EXPERIMENTAL
Intervention: micro-dose rhEpo (20 IU/kg/week)
Number of subjects: 25
Study 28874242 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose rhEpo (60 IU/kg/week)
Number of subjects: 25
Study 28874242 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 25
Study 26813915 — intervention group
Group type: EXPERIMENTAL
Intervention: TEVAR (thoracic endovascular aortic repair)
Number of subjects: 625
Study 26813915 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score calculation for all-cause mortality
Number of subjects: 625
Study 23986461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined methylphenidate therapy and EEG feedback training
Number of subjects: 40
Study 23986461 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate therapy and non‐feedback attention training (Control)
Number of subjects: 40
Study 21733603 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18 g/kg/day citrulline for 7 days
Number of subjects: 12
Study 21733603 — intervention group
Group type: COMPARATOR
Intervention: Placebo (iso-nitrogenous)
Number of subjects: 12
Study 18486778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral vertical ramus osteotomy (IVRO)
Number of subjects: 30
Study 18486778 — intervention group
Group type: COMPARATOR
Intervention: Sagittal split ramus osteotomy (SSRO)
Number of subjects: 30
Study 17178941 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniett device therapy
Number of subjects: 61
Study 12658071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecopipam (0, 30 or 100 mg)
Number of subjects: 10
Study 12658071 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg/70 kg)
Number of subjects: 10
Study 12658071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg/70 kg)
Number of subjects: 10
Study 12658071 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 12658071 — intervention group
Group type: COMPARATOR
Intervention: Ecopipam and Triazolam (compared to placebo)
Number of subjects: 10
Study 11091263 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' method (biweekly phone calls to record calendar information)
Number of subjects: 333
Study 11091263 — intervention group
Group type: COMPARATOR
Intervention: Educators' method (monthly calendar returns)
Number of subjects: 333
Study 8628162 — intervention group
Group type: EXPERIMENTAL
Intervention: MAC (bupivacaine, adrenaline, and cocaine)
Number of subjects: 181
Study 8628162 — intervention group
Group type: COMPARATOR
Intervention: TAC (tetracaine, adrenaline, and cocaine)
Number of subjects: 181
Study 8628162 — intervention group
Group type: EXPERIMENTAL
Intervention: MAC
Number of subjects: 181
Study 8628162 — intervention group
Group type: COMPARATOR
Intervention: TAC
Number of subjects: 181
Study 8628162 — intervention group
Group type: EXPERIMENTAL
Intervention: MAC and TAC
Number of subjects: 181
Study 1451342 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) administered subcutaneously once weekly, dosage titrated to maintain hematocrit at 35-38%.
Number of subjects: 7
Study 1451342 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO)
Number of subjects: 7
Study 1451342 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-comparison)
Number of subjects: 7
Study 6391074 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g zinc sulphate 3 times daily
Number of subjects: 12
Study 6391074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30100295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial technique of the 4th ventricle compression (CV4)
Number of subjects: 30
Study 28951403 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention programme
Number of subjects: 9121
Study 28951403 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 9121
Study 24809305 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for eight weeks
Number of subjects: 20
Study 24809305 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 20
Study 22986112 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prostaglandin analog (latanoprost 0.005%)
Number of subjects: 516
Study 22986112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study 21620591 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatments for cannabis use disorders
Number of subjects: 586
Study 19220066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine extended-release (CER) 30 mg
Number of subjects: 18
Study 19220066 — intervention group
Group type: COMPARATOR
Intervention: Cyclobenzaprine immediate-release (CIR) 10 mg administered every 8 hours for a total of three doses
Number of subjects: 18
Study 16826087 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with true CRS (559 patients)
Number of subjects: 703
Study 16826087 — intervention group
Group type: COMPARATOR
Intervention: Patients classified as normal (144 patients)
Number of subjects: 703
Study 16826087 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with true CRS (460 patients)
Number of subjects: 703
Study 14763665 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-pressure (SP) group - antihypertensive therapy based on home blood pressure measurements.
Number of subjects: 360
Study 14763665 — intervention group
Group type: COMPARATOR
Intervention: Office pressure (OP) group - antihypertensive therapy based on blood pressure measured in the outpatient clinic.
Number of subjects: 360
Study 14763665 — intervention group
Group type: COMPARATOR
Intervention: Cost-minimization analysis of the SP strategy compared to standard practice (OP group).
Number of subjects: 360
Study 14763665 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication compliance recorded in random subgroups of SP and OP groups using MEMS V TrackCaps.
Number of subjects: 360
Study 10866006 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1.0 mg intravenously after 5 min of steady state
Number of subjects: 20
Study 10866006 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride administered after 10 min (group B)
Number of subjects: 20
Study 9200357 — intervention group
Group type: EXPERIMENTAL
Intervention: Infasurf (n = 303, treatment arm)
Number of subjects: 982
Study 9200357 — intervention group
Group type: EXPERIMENTAL
Intervention: Infasurf (n = 180, prevention arm)
Number of subjects: 982
Study 9200357 — intervention group
Group type: COMPARATOR
Intervention: Infasurf and Survanta (both arms)
Number of subjects: 982
Study 1412608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2 g IVPB q 12 h
Number of subjects: 33
Study 1412608 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 1.5 mg/kg IVPB q 8 h plus mezlocillin 4 g IVPB q 6 h
Number of subjects: 33
Study 3929314 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl 10 mg/day
Number of subjects: 11
Study 3929314 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl 30 mg/day
Number of subjects: 11
Study 3929314 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl 60 mg/day
Number of subjects: 11
Study 3929314 — intervention group
Group type: COMPARATOR
Intervention: Tranylcypromine
Number of subjects: 11
Study 29534483 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal deployment condition based on height and tilt angle; noise-filtering scheme for RF signals.
Number of subjects: 0
Study 27737676 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Mile Club® (walking/running program)
Number of subjects: 1200
Study 27737676 — intervention group
Group type: EXPERIMENTAL
Intervention: Just Move™ (classroom-based PA program)
Number of subjects: 1200
Study 27737676 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1200
Study 27737676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (100 Mile Club® and Just Move™)
Number of subjects: 1200
Study 24827514 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (pedicle screw insertion position A)
Number of subjects: 210
Study 24827514 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (pedicle screw insertion position B)
Number of subjects: 210
Study 24827514 — intervention group
Group type: COMPARATOR
Intervention: Group A
Number of subjects: 210
Study 24827514 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 210
Study 22079177 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lactalbumin-enriched and symbiotic-supplemented infant formula
Number of subjects: 97
Study 22079177 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 97
Study 19608168 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrin vaginal insert (two times a day)
Number of subjects: 18
Study 19608168 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrin vaginal insert (three times a day)
Number of subjects: 18
Study 19608168 — intervention group
Group type: COMPARATOR
Intervention: Vaginal gel (daily)
Number of subjects: 18
Study 19608168 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrin treatments (two times and three times a day)
Number of subjects: 18
Study 19608168 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrin vaginal inserts
Number of subjects: 18
Study 18361737 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-calorie CBJ (280 Cal/480 mL)
Number of subjects: 0
Study 18361737 — intervention group
Group type: COMPARATOR
Intervention: Normal-calorie control beverage (HFCS)
Number of subjects: 0
Study 18361737 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie CBJ (38 Cal/480 mL)
Number of subjects: 0
Study 18361737 — intervention group
Group type: EXPERIMENTAL
Intervention: Water (480 mL)
Number of subjects: 0
Study 18361737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nothing (no water/beverage)
Number of subjects: 0
Study 17214336 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum thymidine kinase 1 (S‐TK1) concentration
Number of subjects: 120
Study 17214336 — intervention group
Group type: COMPARATOR
Intervention: Lower serum thymidine kinase 1 (S‐TK1) concentration
Number of subjects: 120
Study 14623542 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg daily and celecoxib 400 mg twice daily (group A)
Number of subjects: 20
Study 14623542 — intervention group
Group type: COMPARATOR
Intervention: Exemestane 25 mg daily (group B)
Number of subjects: 20
Study 14623542 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 2.5 mg daily (group C)
Number of subjects: 20
Study 10768619 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F] fluorodopa uptake in patients with PD
Number of subjects: 28
Study 10768619 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F] fluorodopa uptake in the caudate nucleus
Number of subjects: 28
Study 10768619 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F] fluorodopa uptake in the frontal cortex
Number of subjects: 28
Study 10768619 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of motor symptoms of PD
Number of subjects: 28
Study 8836901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 10 mg.kg‐1.day‐1 and prednisolone 10 mg
Number of subjects: 30
Study 8836901 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid 10 mg.kg‐1.day‐1 and placebo
Number of subjects: 30
Study 1478292 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and recombinant interleukin-2 (IL-2)
Number of subjects: 12
Study 1478292 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study 6491914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 1 mg bumetanide
Number of subjects: 12
Study 6491914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 1 mg bumetanide
Number of subjects: 12
Study 6491914 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution administration of 1 mg bumetanide
Number of subjects: 12
Study 6491914 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet administration of 1 mg bumetanide
Number of subjects: 12
Study 6491914 — intervention group
Group type: COMPARATOR
Intervention: All administration routes
Number of subjects: 12
Study 6491914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular and oral preparations
Number of subjects: 12
Study 31368661 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy diet (HD) - 4 servings or more per day for 6 weeks
Number of subjects: 26
Study 31368661 — intervention group
Group type: COMPARATOR
Intervention: Adequate dairy diet (AD) - 2 servings or less per day for 6 weeks
Number of subjects: 26
Study 28856967 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoSep Novel Collection Bag (N=40)
Number of subjects: 80
Study 28856967 — intervention group
Group type: COMPARATOR
Intervention: C.A.T.S Plus Autotransfusion System (N=40)
Number of subjects: 80
Study 26580489 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg once daily
Number of subjects: 118
Study 26580489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 25293818 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg BW (standard dose or SD group)
Number of subjects: 17
Study 25293818 — intervention group
Group type: COMPARATOR
Intervention: 0.05 mmol/kg BW (half dose or HD group)
Number of subjects: 17
Study 22390457 — intervention group
Group type: COMPARATOR
Intervention: Text message reminders for MCV4 and Tdap immunizations
Number of subjects: 195
Study 22390457 — intervention group
Group type: COMPARATOR
Intervention: Text message and paper-mailed reminders for Hib immunization recall
Number of subjects: 195
Study 22945779 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 mcg)
Number of subjects: 82
Study 22945779 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 mcg)
Number of subjects: 82
Study 17611821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (100 mg per day) along with ferrous sulphate (200 mg per day) and folic acid (5 mg per day) for 3 months
Number of subjects: 100
Study 17611821 — intervention group
Group type: COMPARATOR
Intervention: Control group with ferrous sulphate (200 mg per day) and folic acid (5 mg per day) for 3 months
Number of subjects: 100
Study 16211731 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotrend monitoring (Group NI)
Number of subjects: 30
Study 16211731 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical practice (Group C)
Number of subjects: 30
Study 11838797 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium miniplate fixation
Number of subjects: 40
Study 11838797 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel wire fixation
Number of subjects: 40
Study 10429902 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote interactive fiber‐optic NPL
Number of subjects: 0
Study 10429902 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine applications in otolaryngology
Number of subjects: 0
Study 7478837 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized developmental care
Number of subjects: 36
Study 7478837 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 36
Study 2147234 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 112
Study 2147234 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 112
Study 6108751 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-acetylenic GABA (GAG)
Number of subjects: 10
Study 28549180 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perception of aging (SPA)
Number of subjects: 1216
Study 28549180 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 1216
Study 28568169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 0.05 mg/kg IM q24h
Number of subjects: 8
Study 28568169 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (FLUT) 3,000 μg q12h
Number of subjects: 8
Study 26382998 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oximeters (oxygen given if SpO2 <94%)
Number of subjects: 615
Study 26382998 — intervention group
Group type: COMPARATOR
Intervention: Modified oximeters (oxygen given if SpO2 <90%)
Number of subjects: 615
Study 24108521 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 19
Study 24108521 — intervention group
Group type: COMPARATOR
Intervention: abobotulinumtoxinA
Number of subjects: 19
Study 20824706 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV triaging policy
Number of subjects: 3319
Study 20824706 — intervention group
Group type: COMPARATOR
Intervention: Colposcopy policy
Number of subjects: 3319
Study 19389262 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and placebo medicine
Number of subjects: 140
Study 19389262 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture and Flunarizine (10 mg once per night for the first 2 weeks, then 5 mg once per night for the next 2 weeks)
Number of subjects: 140
Study 18181333 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV vaccine trial with education and risk reduction counseling every six months
Number of subjects: 2546
Study 15127144 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Number of subjects: 0
Study 15127144 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 11808370 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline application for 5 s
Number of subjects: 72
Study 11808370 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline application for 10 s
Number of subjects: 72
Study 11808370 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline application for 30 s
Number of subjects: 72
Study 11808370 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline application for 1 min
Number of subjects: 72
Study 11808370 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline application for 2 min
Number of subjects: 72
Study 11808370 — intervention group
Group type: COMPARATOR
Intervention: Citric acid application for 3 min
Number of subjects: 72
Study 11808370 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnishing with saline for 5 s
Number of subjects: 72
Study 11808370 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnishing with saline for 10 s
Number of subjects: 72
Study 11808370 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnishing with saline for 1 min
Number of subjects: 72
Study 11808370 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnishing with saline for 2 min
Number of subjects: 72
Study 9674806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 60 mg p.o., five times daily
Number of subjects: 41
Study 9674806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg p.o., three times daily
Number of subjects: 41
Study 9674806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 7985514 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyrine in Tibetan
Number of subjects: 33
Study 7985514 — intervention group
Group type: COMPARATOR
Intervention: Antipyrine in Han
Number of subjects: 33
Study 7985514 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen in Tibetan
Number of subjects: 33
Study 7985514 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen in Han
Number of subjects: 33
Study 2692576 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunostimulant
Number of subjects: 284
Study 2692576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 810765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 20
Study 810765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 810765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium on study day 2 after placebo on study day 1
Number of subjects: 20
Study 31415908 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 RA exenatide (acute administration)
Number of subjects: 0